Table 2.

Uni- and multivariable hazard ratios for MVP score and BCR, clinical progression and PCSM

		Univariable analysis		Multivariable analysisa
Covariate	No. of events/total	HR (95% CI)	P value	HR (95% CI)	P value
BCR
MVP score
Low	84/250	Reference		Reference
High	59/118	1.62 (1.16–2.27)	0.004	1.64 (1.17–2.29)	0.004
CAPRA-S score
0–2	21/108	Reference		Reference
3–5	65/183	1.95 (1.19–3.19)	0.008	2.06 (1.25–3.37)	0.004
≥6	57/77	6.19 (3.74–10.23)	<0.001	5.56 (3.34–9.28)	<0.001
PNI
Negative	87/276	Reference		Reference
Positive	56/92	2.32 (1.65–3.24)	<0.001	1.70 (1.20–2.41)	0.003
Clinical progression
MVP score
Low	22/250	Reference		Reference
High	20/118	1.88 (1.02–3.47)	0.044	2.06 (1.11–3.82)	0.021
CAPRA-S score
0–2	3/108	Reference		Reference
3–5	20/183	4.01 (1.19–13.50)	0.024	4.39 (1.30–14.83)	0.017
≥6	19/77	8.21 (2.41–27.93)	<0.001	7.39 (2.14–25.48)	0.001
PNI
Negative	23/276	Reference		Reference
Positive	19/92	2.34 (1.26–4.34)	0.007	1.85 (0.97–3.53)	0.063
PC-specific mortality
MVP score
Low	5/250	Reference		Reference
High	9/118	4.22 (1.40–12.67)	0.010	4.41 (1.45–13.38)	0.009
CAPRA-S score
0–2	2/108	Reference		Reference
3–5	5/183	1.27 (0.24–6.60)	0.774	1.49 (0.28–7.75)	0.637
≥6	7/77	4.05 (0.83–19.72)	0.083	3.47 (0.69–17.44)	0.130
PNI
Negative	6/276	Reference		Reference
Positive	8/92	3.58 (1.23–10.43)	0.019	2.70 (0.88–8.19)	0.079

CI, confidence interval; HR, hazard ratio.

^aAdjusted for CAPRA-S score and PNI (perineural invasion).